Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks leukemia Drug's Real-Life impact

NCT ID NCT03987958

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 100 adults with acute myeloid leukemia (AML) who are already prescribed venetoclax by their doctors in Israel. Researchers will track how long patients live and how many achieve remission during routine care. The goal is to understand the drug's real-world effectiveness and safety outside of controlled trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2019

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with AML treated with venetoclax in routine clinical practice

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant diagnosed with Acute Myeloid Leukemia (AML) and is eligible to receive venetoclax per Israel Ministry of Health. * Participant who will be treated with venetoclax and the decision to treat with venetoclax is made by the physician prior to any decision regarding participation in this study. Exclusion Criteria: \- Participant participating in an interventional trial within 30 days prior to starting venetoclax treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia

Contacts and locations

Locations

  • Assuta Tel Aviv Medical Center /ID# 213371

    Tel Aviv, Central District, 6971028, Israel

  • Bnai Zion Medical Center /ID# 213344

    Haifa, 3339419, Israel

  • HaEmek Medical Center /ID# 213370

    Afula, Haifa District, 1834111, Israel

  • Hadassah /ID# 213356

    Jerusalem, Jerusalem, 91120, Israel

  • Meir Medical Center /ID# 213352

    Kfar Saba, Central District, 4428164, Israel

  • Rabin Medical Center. /ID# 213343

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus /ID# 213355

    Haifa, 3109601, Israel

  • Shaare Zedek Medical Center /ID# 228016

    Jerusalem, Jerusalem, 91031, Israel

  • Soroka University Medical Center /ID# 213369

    Beersheba, Southern District, 8443901, Israel

  • Tel Aviv Sourasky Medical Center /ID# 213354

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Chaim Sheba Medical Center /ID# 213353

    Ramat Gan, Tel Aviv, 5265601, Israel

  • ZIV Medical Center /ID# 229211

    Safed, Northern District, 13100, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.